Study of 0.4% povidone-iodine nasal spray for SARS-CoV-2
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
Source: dovepress.com
Stay updated with breaking news from Commons Attribution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
Effect of Singing on Symptoms in Stable COPD: A Systematic Review and Meta-Analysis
Hypertension and Dyslipidaemia in Argentina: Patient Journey Stages